Back to search

National and Kapodistrian University of Athens

Θεραπείες νεφρικής υποκατάστασης σε ασθενείς με τελικού σταδίου καρδιακή ανεπάρκεια και καρδιονεφρικό σύνδρομο

Abstract

dc:description

Background Renal replacement therapies represent an alternative method of decongestion in heart failure patients with cardiorenal syndrome and refractory congestion despite diuretic therapy. Although there are a lot of trials concerning ultrafiltration therapy in acute heart failure decompensation, most of them with positive results, the bibliographic data of chronic, intermittent renal replacement therapy in end stage heart failure patients with cardiorenal syndrome type 2 and diuretic resistance are few. Aim The aim of this study is to investigate the role of renal replacement therapies in the management of chronic end-stage heart failure patients with type 2 cardiorenal syndrome, diuretic resistance and refractory systemic or pulmonary congestion. Patients and methods 45 consecutive patients with severe end-stage heart failure, low cardiac output and congestion were included in this study. The patients were divided in two groups according to the presence or not of resistance to per os diuretics. 20 patients who responded to per os diuretics were treated with intermittent 8-hour sessions of dobutamine 10μg/kgr/min, levosimendan 0,2μg/kgr/min or combination (Group Ι). 25 patients with diuretic resistance, defined as refractory congestion despite more than 500mg furosemide daily, were treated with the same inotrope agents and doses as Group I in addition to intermittent extracorporeal fluid removal in terms of continuous venovenous hemofiltration at first and accordingly as out of hospital intermittent ultrafiltration, through permanent internal jugular catheters (Group RRT). Patients of both groups were followed up prospectively in the heart failure clinic for at least one year. Results The patients’ baseline characteristics between the two groups were as followed : Patients mean age was 56±12 versus 62±11 years (p=0,12). Heart failure cause was ischemic cardiomyopathy in 11 patients of group I and in 9 patients of group RRT while idiopathic dilated cardiomyopathy was the cause in 9 patients of group I and in 16 patients of group RRT (p=0,16). ΝΥΗΑ functional class was 3,2±0,7 versus 3,5±0,5 in two groups respectively (p=0,14). Left ventricular ejection fraction as measured by transthoracic echocardiogram was 23,5%±5% versus 26,3%±6%, respectively (p=0,1). Systolic blood pressure was 95±12mmHg versus 99±13mmHg respectively(p=0,3), mean right atrial pressure as measured in right heart catheterization was significantly different between patients of the two groups, 14,2±5mmHg versus 19,2±6mmHg (p=0,01), and no differences were found between pulmonary artery systolic pressure, 60±19mmHg versus 54±13mmHg, p=0,3, pulmonary capillary wedge pressure, 29±6mmHg versus 26±5mmHg, p=0,2 and cardiac index, 1,7±0,4Lt/min/m2 versus 1,7±0,5Lt/min/m2, p=0,9, respectively. BNP was 1654 ±1482pg/ml versus 1494±1313pg/ml, p=0,7, serum creatinine 1,7±0,8mg/dl versus 2,1±0,7mg/dl, p=0,1 and serum sodium 135±6mEq/Lt versus 134±5mEq/Lt, p=0,7. Significant differences were found in serum hemoglobulin, 12,5±1,4 g/dl versus 11,1±1,2g/dl, p=0,001 and daily peros dose of furosemide 451±208mg versus 590±188mg, p=0,03. Patients of RRT group were found to have a significantly lower risk of hospitalization in 6 months HR=0,26 (CI 95% 0,1-0,6), p=0,001 and in one year follow up HR : 0,3 CI 95% 0,15-0,67, p-0,003). Mean six month survival free of death or LVAD implantation was 16,5 weeks in group Ι patients versus 22,6 weeks in group RRT patients ( log rank test, p=0,014). Mean one year survival was 25,4 weeks versus 40 weeks for two groups respectively (log rank test: p=0,01). Conclusion In this prospective, non randomized study of end-stage heart failure patients with cardiorenal syndrome, intermittent renal replacement therapy was associated with significantly less morbidity and improved survival free of severe adverse events during one year follow up. Intermittent extracorporeal fluid removal could represent an efficient method of treating refractory congestion in this kind of patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Repasos, Evangelos
  • Ρεπάσος, Ευάγγελος

Subjects

dc:subject × 10

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/39759

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Repasos, Evangelos; Ρεπάσος, Ευάγγελος. Θεραπείες νεφρικής υποκατάστασης σε ασθενείς με τελικού σταδίου καρδιακή ανεπάρκεια και καρδιονεφρικό σύνδρομο. National and Kapodistrian University of Athens, 2016. http://hdl.handle.net/10442/hedi/39759